Alice Bendix Gottlieb MD, PhD

Alice Bendix Gottlieb MD, Ph.D. is a Medical Director at Mount Sinai Beth Israel Dermatology, Kimberly and Eric J. Waldman Department of Dermatology at The Icahn School of Medicine at Mount Sinai, is a superb physician who has made a significant mark in the scientific fields of Dermatology and Rheumatology.

<br/><br/>

After graduating from Brandeis University Summa Cum Laude with Honors in Chemistry, Dr. Gottlieb entered the combined MD-PhD program at Rockefeller University-Cornell University Medical College where she was one of the first females to be admitted into the program. She received her Ph.D. from Rockefeller University in 1979 followed by her MD at Cornell University Medical Center in 1980. Dr. Gottlieb entered The New York Hospital for her internal medicine residency, which she completed in 1982, followed by a rheumatology fellowship at the Hospital for Special Surgery completed in 1984, and returned to the New York Hospital for her dermatology residency which she completed in 1993. 

<br/><br/>

Dr. Gottlieb founded the Tufts Dermatology residency program (which formally was shared with Boston University) and served as Chair of Dermatology and Dermatologist-in-Chief of Tufts Medical Center. She also founded the Dermatology Division at UMDNJ-Robert Wood Johnson Medical School where she served as Professor of Medicine, Director of the Clinical Research Center, and Founding Director of the Psoriasis Center of Excellence. Before joining the Mt Sinai faculty she was a Professor of Dermatology at New York Medical College in New York City.

<br/><br/>

Dr. Gottlieb is an internationally recognized expert in the field of psoriasis and psoriatic arthritis. Her research uses targeted immunobiology as pathogenic probes, providing a new understanding of the pathogenesis of psoriasis and providing the foundation for biological drug development in these two debilitating diseases. Through a study she had published in Lancet in 2001, Dr. Gottlieb was the first to show the efficacy of TNF blockers as monotherapy for moderate to severe psoriasis Her research led to multiple TNF blockers being FDA-approved for psoriasis which revolutionized the care of psoriasis, and psoriatic arthritis patients.